Compare MSGE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | IMNM |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | MSGE | IMNM |
|---|---|---|
| Price | $59.27 | $22.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $52.40 | $31.22 |
| AVG Volume (30 Days) | 282.9K | ★ 2.5M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $962,282,000.00 | $9,679,000.00 |
| Revenue This Year | $9.47 | N/A |
| Revenue Next Year | $5.52 | $11.53 |
| P/E Ratio | $82.63 | ★ N/A |
| Revenue Growth | ★ 0.68 | N/A |
| 52 Week Low | $28.29 | $5.15 |
| 52 Week High | $61.64 | $25.30 |
| Indicator | MSGE | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 72.58 | 60.67 |
| Support Level | $58.79 | $20.05 |
| Resistance Level | $61.64 | $22.01 |
| Average True Range (ATR) | 1.63 | 1.28 |
| MACD | 0.42 | 0.04 |
| Stochastic Oscillator | 73.93 | 82.00 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.